|Bid||177.04 x 800|
|Ask||177.24 x 900|
|Day's range||176.86 - 178.12|
|52-week range||155.72 - 186.69|
|Beta (5Y monthly)||0.57|
|PE ratio (TTM)||24.69|
|Earnings date||24 Jan 2023|
|Forward dividend & yield||4.52 (2.55%)|
|Ex-dividend date||21 Nov 2022|
|1y target est||183.10|
You can count on them to pay dividends quarter after quarter as well as deliver solid growth over the long term. Here's why they picked AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), and Johnson & Johnson (NYSE: JNJ).
The stock market has been fairly volatile over the past three years, which isn't surprising given the worldwide crises we have experienced. Let's look at two that fit the bill: Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV). Johnson & Johnson is one of the largest healthcare companies in the world, and typically generates higher sales than most other pharmaceutical peers.
Most investors are more than ready for stocks to take off in a new bull market. Vertex Pharmaceuticals (NASDAQ: VRTX) is heading for its biggest catalyst in a long while. First, it marks Vertex's move beyond its cystic fibrosis (CF) specialty into another treatment area.